30 reports of this reaction
1.7% of all BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE reports
#11 most reported adverse reaction
ARTHRALGIA is the #11 most commonly reported adverse reaction for BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, manufactured by ANI Pharmaceuticals, Inc.. There are 30 FDA adverse event reports linking BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE to ARTHRALGIA. This represents approximately 1.7% of all 1,767 adverse event reports for this drug.
Patients taking BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE who experience arthralgia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ARTHRALGIA is a less commonly reported adverse event for BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, but still significant enough to appear in the safety profile.
In addition to arthralgia, the following adverse reactions have been reported for BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE:
The following drugs have also been linked to arthralgia in FDA adverse event reports:
ARTHRALGIA has been reported as an adverse event in 30 FDA reports for BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ARTHRALGIA accounts for approximately 1.7% of all adverse event reports for BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, making it a notable side effect.
If you experience arthralgia while taking BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.